Aligos Therapeutics (ALGS) Stock Chart & Stock Price History $9.06 +0.16 (+1.74%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Aligos Therapeutics Stock Price Performance The Aligos Therapeutics (ALGS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 32.85%, with a year-to-date return of -77.25%. In the past month, the stock has increased 18.81%, reflecting recent market activity. As of the latest close, Aligos Therapeutics traded at $8.91 with a market cap of $54.44 million and volume of 38,504 shares. Receive ALGS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.04%1 Month Performance+18.81%3 Month Performance+66.33%Year-To-Date Performance-77.25%1 Year Performance-32.85% ALGS Stock Chart for Friday, July, 25, 2025 ALGS Chart by TradingView Aligos Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/24/2025$9.28$8.91-3.99%$9.11$8.6738,504 shs$54.44 million07/23/2025$9.12$9.28+1.75%$9.44$8.9446,007 shs$56.74 million07/22/2025$8.64$9.12+5.56%$9.22$8.1881,117 shs$55.72 million07/21/2025$9.16$8.64-5.68%$9.92$8.64170,696 shs$52.79 million07/18/2025$9.04$9.16+1.33%$9.48$8.8479,665 shs$55.97 million07/17/2025$8.68$9.04+4.15%$9.30$8.61131,332 shs$55.23 million07/16/2025$8.50$8.68+2.12%$8.69$8.2056,517 shs$53.07 million07/15/2025$8.69$8.50-2.19%$8.95$8.2650,714 shs$51.94 million07/14/2025$8.36$8.69+3.95%$8.80$8.1355,283 shs$53.10 million07/11/2025$8.79$8.36-4.89%$8.85$8.2660,315 shs$51.08 million Get the Latest News and Ratings for ALGS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/10/2025$8.66$8.79+1.50%$8.88$8.4353,589 shs$53.74 million07/09/2025$8.24$8.66+5.10%$9.10$8.18289,194 shs$52.91 million07/08/2025$7.50$8.24+9.87%$8.50$7.60133,814 shs$50.35 million07/07/2025$7.95$7.50-5.66%$7.74$7.3057,579 shs$45.83 million07/04/2025$7.95$7.95$8.06$7.2596,005 shs$48.57 million07/03/2025$7.31$7.95+8.76%$8.06$7.2596,005 shs$48.61 million07/02/2025$7.39$7.31-1.08%$7.75$7.1751,768 shs$44.66 million07/01/2025$7.21$7.39+2.50%$7.42$6.8267,251 shs$45.15 million06/30/2025$7.21$7.21$7.44$7.0057,952 shs$44.05 million06/27/2025$7.14$7.21+0.98%$7.46$6.8887,518 shs$44.05 million06/26/2025$7.63$7.14-6.42%$7.68$7.1171,721 shs$43.63 million06/25/2025$8.24$7.63-7.40%$8.54$7.42141,292 shs$46.62 million06/24/2025$7.18$8.24+14.76%$8.66$7.21137,528 shs$50.38 million Related Companies Eledon Pharmaceuticals Stock Chart MediWound Stock Chart biote Stock Chart CARGO Therapeutics Stock Chart Neoleukin Therapeutics Stock Chart AC Immune Stock Chart Larimar Therapeutics Stock Chart Canopy Growth Stock Chart 4D Molecular Therapeutics Stock Chart Y-mAbs Therapeutics Stock Chart Receive ALGS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALGS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
